Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference29 articles.
1. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer;Ray-Coquard;N. Engl. J. Med.,2019
2. Niraparib in patients with newly diagnosed advanced ovarian cancer;González-Martín;N. Engl. J. Med.,2019
3. Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry;Wiegand;J. Chromatogr. B Anal. Technol. Biomed. Life Sci.,2010
4. Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial;Li;J. Clin. Oncol.,2022
5. Pamiparib monotherapy for patients with germline BRCA1/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase II study;Wu;Clin. Cancer Res.,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献